Cephalon, Inc. v. Nang Kuang Pharmaceutical Co LTD
1:14-cv-01117
Overview
Parties
Defendant
Nang Kuang Pharmaceutical Co LTD Operating Company
Represented By
0 Attorneys ListedPlaintiff
Cephalon, Inc. Operating Company
Represented By
3 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Shaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi USA, LLC v. Cephalon, Inc.
AGILA SPECIALTIES INC. et al. v. Cephalon, Inc.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8445524
Solid forms of bendamustine hydrochloride
|
Filed: 2011-11-22
Issued: 2013-05-21
|
Active (5.0 yrs remaining)
Expires: 2031-11-22
|
|
|
US8436190
Bendamustine pharmaceutical compositions
|
Filed: 2006-01-12
Issued: 2013-05-07
|
Active (3.9 yrs remaining)
+1748d PTA
Expires: 2030-10-26
|
|
|
US8609863
Bendamustine pharmaceutical compositions
|
Filed: 2012-12-19
Issued: 2013-12-17
|
Active (6.1 yrs remaining)
Expires: 2032-12-19
|
|
|
US8791270
Bendamustine pharmaceutical compositions
|
Filed: 2013-08-19
Issued: 2014-07-29
|
Active (6.7 yrs remaining)
Expires: 2033-08-19
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings